title: Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition.
abstract: Patients receiving tumour necrosis factor alpha (TNF-α) inhibitors are at increased risk of exacerbation of (myco-)bacterial and some viral infections. However, information on anogenital human papillomavirus (HPV) infection in these patients is sparse or conflicting. In this study 222 patients with psoriasis or inflammatory bowel disease (IBD), who received either anti-TNF-α inhibitors or alternatives (purine-, folic acid analogues, phototherapy, fumaric ester, mesalazine) continuously for at least 6 months, were evaluated for the presence of anogenital HPV-induced lesions, mucosal HPV DNA, and serological status of mucosal low-risk HPV6 and high-risk HPV16/HPV18. Hallmarks of anogenital HPV infection were more frequently detected in patients with psoriasis than in those with IBD. HPV-induced lesions, viral DNA, and seroprevalence were not elevated in participants with psoriasis or IBD, who received TNF-α inhibitors for a mean duration of 31.4 months (range 6-96 months) compared with recipients of alternative or no treatment. TNF-α blockade for a mean period of 31.4 months does not increase detectable anogenital HPV infection or disease.
authors.affiliation: Department of Dermatology, Medical University Vienna, AT-1090 Vienna, Austria. alessandra.handisurya@meduniwien.ac.at.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Handisurya
authors.forename: Stefanie
authors.initials: S
authors.lastname: Lázár
authors.forename: Pavol
authors.initials: P
authors.lastname: Papay
authors.forename: Christian
authors.initials: C
authors.lastname: Primas
authors.forename: Andrea
authors.initials: A
authors.lastname: Haitel
authors.forename: Reinhard
authors.initials: R
authors.lastname: Horvat
authors.forename: Adrian
authors.initials: A
authors.lastname: Tanew
authors.forename: Harald
authors.initials: H
authors.lastname: Vogelsang
authors.forename: Reinhard
authors.initials: R
authors.lastname: Kirnbauer
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001004:Anus Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology / Q000821:virology; D001317:Austria / Q000453:epidemiology; D003218:Condylomata Acuminata / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology / Q000821:virology; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D008297:Male; D008875:Middle Aged; D027383:Papillomaviridae / Q000276:immunology; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology / Q000821:virology; D015995:Prevalence; D011446:Prospective Studies; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D060737:Reproductive Tract Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology / Q000821:virology; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha